1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Unresectable Digestive System Adenocarcinoma: new trials by email Literature Review of Unresectable Digestive System Adenocarcinoma trials Research Report on Unresectable Digestive System Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TAS102 in Combination With NAL-IRI in Advanced GI Cancers Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride - Colorectal Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Emory University | 64 | 2018-01-30 | 2025-01-07 |
Colorectal Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Pancreatic Diseases (1) · Rectal Diseases (1) · Stomach Diseases (1)
Irinotecan (1) · Trifluridine (1) · irinotecan sucrosofate (1) · trifluridine tipiracil drug combination (1)
Emory University (1)
United States (1)